drugset / Trial / NCT01437540

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01437540

Phase 3 Completed 590 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).

Timeline

Start
2011-09-19
Primary completion
2013-03-31
Completion
2013-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclidinium Small molecule 400 ug Inhaled
Comparator Formoterol Other / unclassified 12 ug Inhaled